Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Matthew Herper covers ...

Valneva has reported phase 2 data on the third booster dose of its Pfizer-partnered Lyme disease vaccine candidate, ticking off another task for a prospect that could reach regulatory review next year ...

Pfizer said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker's attempt to outbid Pfizer to acquire the obesity biotech is anticompetitive. The new suit ...

Pfizer’s VC arm has backed a $100 million series A raise for OTR Therapeutics as the Chinese biotech tacks on preclinical neurological assets to its varied portfolio. Shanghai-based OTR raised the ...

Pfizer said it has struck an up to $2.1 billion licensing deal with YaoPharma to develop and commercialize its obesity pill, furthering the pharma company's push into the weight loss space.

LONDON (Reuters) -Metsera has become the obesity drug market's hottest ticket. The New York-based biotech is at the centre of a bidding war between Novo Nordisk and Pfizer, both vying for access to ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Investors are weighing Pfizer’s stable dividend and oncology-focused growth strategy against the higher-risk, higher-reward potential of biotech firms. Pfizer is navigating a post-COVID revenue ...

COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer as the drugmakers jostled for advantage in the ...